Iliadin Lub

Quick links

Choose a section

Quick links to important sections

Advertisements

Iliadin Lub

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Iliadin Lub

Quick Facts

Property Description
Active Ingredients Oxymetazoline, Dexpanthenol
Form Nasal drops / Nasal spray (Aqueous topical solution)
Pharmacological Class Alpha-Adrenergic Agonist & Epithelial Protectant Combination
Route of Administration Topical Intranasal
Origin Synthetic/Derived

Defining Iliadin Lub: A Combination Nasal Solution

Iliadin Lub is defined as a fixed-dose combination medicinal product intended for topical intranasal administration. This preparation is formulated as an aqueous solution, delivered directly to the nasal mucosa. Its pharmacological class is a blend of a potent nasal decongestant and an epithelial protectant. The decongestant component, Oxymetazoline, is classified as an alpha-adrenergic agonist, targeting nasal vasculature.

Active Ingredients and Dual-Action Purpose

The preparation's efficacy stems from its two Active Ingredients [INN]: the synthetic vasoconstrictor Oxymetazoline and the derived/synthetic pro-vitamin Dexpanthenol. The primary purpose is twofold: Oxymetazoline induces rapid vasoconstriction to physically relieve nasal congestion, while Dexpanthenol is integrated to promote mucosal integrity restoration. The inclusion of Dexpanthenol is clinically recognized for its role in cell proliferation and wound healing, providing a distinctive benefit in this type of topical preparation.

How Iliadin Lub Differs from Single-Ingredient Decongestants

The combination structure of Iliadin Lub distinguishes it from common, single-ingredient nasal decongestants that operate solely via the vasoconstrictor mechanism. Such single-agent preparations aim exclusively at reducing mucosal swelling. By contrast, the addition of the Epithelial Protectant shifts the product's focus. Research has supported the beneficial effect of Dexpanthenol, confirming that its presence helps mitigate damage to the delicate ciliated epithelium that may occur during the treatment of acute rhinitis. This approach is specifically designed to achieve rapid physical decongestion while actively supporting the physiological recovery of the epithelium, reinforcing the product’s design for both relief and mucosal care.

Advertisements

What side effects are possible with Iliadin Lub?

Possible side effects and safety information

The safety profile of this combination nasal solution is primarily derived from the documented effects of its decongestant component, Oxymetazoline, as formally classified in regulatory documents.

Adverse Reaction Scope

The adverse reactions are grouped by System-Organ Class, with local effects typically classified as more common and systemic effects associated with prolonged use or overexposure.

Classification Examples of Documented Effects
Frequent (Common) Aqueous nasal secretions, Crusted nose.
Less frequent (Uncommon) Rebound congestion, Headache, Nervousness, Irritability.
Frequency Unknown Insomnia, Hypertension, Palpitations, Tachycardia, Hypersensitivity reactions (e.g., angioedema), Nasal discomfort (burning), Sneezing, Epistaxis, Fatigue.

Serious adverse reactions, though rare at therapeutic use, are officially documented outcomes of prolonged administration or overdose and involve the central nervous and cardiovascular systems, including events such as convulsions, coma, severe hypertension, cardiac dysrhythmia, and cardiac arrest.

Safety Constraints and Considerations

Safety-Related Restrictions: Official regulatory labels document constraints against use in patients with certain pre-existing conditions, including severe cardiovascular diseases (e.g., severe hypertension, coronary heart disease), narrow-angle glaucoma, Phaeochromocytoma, and conditions following surgery that exposed the dura mater (e.g., post transsphenoidal hypophysectomy).

Time- and Exposure-Related Patterns: The regulatory safety framework explicitly highlights that rebound congestion (Rhinitis medicamentosa) and tachyphylaxis (reduced efficacy) are safety consequences associated with continuous or long-term use. Furthermore, reactive hyperaemia (increased swelling) may occur after the decongestant effect subsides.

Population-Specific Notes: The safety profile emphasizes that in the pediatric population, accidental or excessive systemic exposure is known to result in severe Central Nervous System (CNS) effects such as convulsions and coma.

Regulatory Safety Summary

The official safety information structures the understanding of risks by clearly segmenting common, local adverse effects from the potential serious systemic risks of cardiovascular and CNS events that are associated with high or prolonged exposure. The profile emphasizes that safety is contingent upon appropriate context, necessitating restrictions for use in patients with pre-existing conditions sensitive to alpha-adrenergic stimulation, as explicitly documented in regulatory labels.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This section describes officially documented overdose manifestations and mandated emergency actions based on government regulatory labeling for the active ingredient, Oxymetazoline.

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations: Symptoms may include mydriasis (pupil dilation), fever, spasms, convulsions, nervousness, and psychic disturbance. CNS depression can manifest as somnolence, lowering of body temperature, and loss of consciousness.
Physiological systems affected: Nervous System (CNS), Cardiovascular System, Respiratory System, and Thermoregulatory System.
Dose-related or exposure-related factors: Toxicity is mainly due to systemic absorption following accidental oral ingestion, even of small amounts (e.g., 1–2 mL).
Population-specific overdose notes: Children 5 years of age and younger are specifically susceptible to severe and life-threatening systemic effects.
Emergency-response statements: Seek emergency medical care immediately following accidental oral ingestion.
When immediate medical help is required: When accidental swallowing occurs, or if severe manifestations such as coma, decreased heart rate (bradycardia), or decreased breathing (apnoea) are observed.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification: Potential for severe and life-threatening adverse events.
Regulatory basis: Based on official Summary of Product Characteristics (SmPC) and government drug safety communications.
Overdose-context constraints: Toxicity is primarily defined by the systemic effects of alpha-adrenergic agonism.

Resulting Overdose Structure

Official overdose statements:

  • The cardiovascular system may exhibit effects including tachycardia, cardiac arrhythmia, hypertension, and subsequent shock-like hypotension.
  • Supportive treatment is required; procedures documented in regulatory texts may include gastric emptying, activated charcoal administration, and a saline laxative.
  • Monitoring of vital signs, including blood pressure and pulse, is required in the event of an overdose.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile by the serious risk of CNS and cardiopulmonary instability following systemic absorption. Official guidance mandates immediate emergency medical care when accidental ingestion occurs, particularly in the pediatric population, due to the documented potential for life-threatening outcomes like coma and respiratory depression.

Advertisements

Therapeutic Uses of Iliadin Lub

What Iliadin Lub Treats: Main Uses and Benefits

Targeting Acute Nasal Blockage and Pressure

This combination preparation is primarily used to provide supportive, temporary symptomatic relief from the physical discomfort of nasal obstruction and congestion, which generally manifests as a stuffy nose and localized sinus pressure. It is applied in conditions where sudden, heightened symptoms—such as those from the common cold or allergic rhinitis—are interfering with comfortable breathing and daily comfort.

The therapeutic application is relevant for easing symptoms associated with acute rhinitis, allergic rhinitis, and postoperative nasal care.

“This formulation is commonly used to address groups of symptoms that may appear suddenly and create noticeable physiological strain.”

Supportive Management for Mucosal Health

Iliadin Lub is relevant in therapeutic contexts where additional symptomatic support is needed, particularly for the integrity and healing of the nasal mucosa. This is critical for conditions involving inflammatory or irritative processes, such as acute rhinitis or periods following nasal procedures. This dual-action approach supports the patient during difficult episodes and contributes to easing the overall symptom load by supporting local tissue health and may help provide local comfort.


Quick Fact: Relief for Nasal and Sinus Congestion

Therapeutic Focus Indicated Contexts Primary Symptom Relief
Symptomatic Decongestion Acute rhinitis (common cold), Allergic rhinitis Stuffy nose, Nasal blockage, Sinus pressure
Epithelial Support Irritative states, Postoperative recovery Mucosal discomfort, Inflammation, Tissue vulnerability

Regulatory References

  1. UK Medicines and Healthcare products Regulatory Agency (MHRA) documentation
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Status

The use of this medicine is defined by explicit population eligibility rules detailed in regulatory documents.

Population Status Classification
Established Use Adults and children six years of age and older.
Conditional Use Pregnancy, Lactation, and individuals with specific systemic conditions.
Prohibited Use Children under six years, MAOI users, and patients with certain comorbidities.

Who Cannot Use the Medicine (Contraindications)

The medicine is absolutely contraindicated for patients with known hypersensitivity to the active ingredients, narrow-angle glaucoma, or rhinitis sicca. An absolute prohibition is enforced for individuals currently using or who have used Monoamine Oxidase Inhibitors (MAOIs) within the past 14 days. Use is also contraindicated in patients with severe cardiovascular diseases or following specific surgical procedures (e.g., trans-sphenoidal hypophysectomy).

Use with Caution and Restrictions

Conditional use is required for individuals with specific pre-existing conditions. Caution is necessary for patients with hypertension, diabetes mellitus, hyperthyroidism, or prostatic enlargement. Additionally, the official label states that the medicine should only be used after consultation with a medical practitioner during both pregnancy and lactation.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for this combination nasal solution is primarily defined by the sympathomimetic activity of the decongestant component, Oxymetazoline.

Interaction Category Official Regulatory Classification
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs)
Pharmacodynamic Risk Tricyclic Antidepressants (TCAs), Nonselective Beta-Adrenergic Antagonists
Exposure Modification Risk Low (Minimal systemic metabolism)

Official Interaction Statements

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), or use within two weeks of stopping an MAOI, is formally contraindicated by regulatory documents. This severe restriction is due to a pharmacodynamic interaction that creates a significant risk of a hypertensive crisis.

Other medicines that affect the vascular system, such as Tricyclic Antidepressants (TCAs) and Nonselective Beta-Adrenergic Antagonists, carry a warning because co-use may cause additive vasopressor effects, potentially leading to elevated blood pressure.

Regulatory reviews confirm that, due to the topical administration route, the drug has a low potential for clinically significant pharmacokinetic interactions involving common metabolic enzymes (e.g., CYP), meaning it is unlikely to alter the systemic clearance of most co-administered medicines. Official labeling may also include timing rules, such as requiring a 24-hour separation, before using certain other nasal products. Furthermore, while not drug-drug interactions, cautions are formally documented for use in patients with pre-existing conditions sensitive to sympathomimetic effects, including hypertension, heart disease, and thyroid disease.

Advertisements

Mechanism of Action

Targeted Activation of Local Vascular Receptors

The primary mechanism is the rapid activation of specific α-adrenoceptors on the vascular smooth muscle in the nasal lining by Oxymetazoline. Acting as a direct agonist, this molecular interaction initiates a signaling cascade that causes the local blood vessels to rapidly vasoconstrict (narrow). This physiological change reduces the volume of fluid and swelling in the mucosal tissue, a response that functionally contributes to reduced nasal airway resistance.


Metabolic Support for Epithelial Integrity

A second, complementary mechanism involves Dexpanthenol, a pro-vitamin that is converted by local cellular metabolism into Coenzyme A (CoA). CoA is an essential cofactor that supports the cellular proliferation and metabolic processes required for the formation and repair of the delicate nasal epithelial barrier. This action influences the integrity of the mucosal lining by supporting the maintenance of tissue structure and contributing to the physiological process of re-epithelialization.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Iliadin Lub is strictly designated for Topical Intranasal administration as an aqueous topical solution, applied directly to the nasal mucosa. The usage is structured around a short-term, highly restricted pattern established for this type of decongestant combination.


Dosing and Frequency Limits

Administration is generally intended for adults and children who are 6 years of age and older. The standard application involves administering 2 or 3 sprays or drops into each nostril. The dosing frequency is mandated to be not more often than every 10 to 12 hours, with a strict maximum of 2 doses in any 24-hour period.


Procedural and Duration Constraints

The product is explicitly labeled for short-term use only, with guidance indicating that treatment should not exceed 3 consecutive days. Continued or prolonged application falls outside of the established use protocol. Prior to application, the nasal passages must be cleared. If a spray device is used, it must be primed by depressing the pump several times before the first use to ensure proper delivery of the metered dose. The dispenser is limited to use by only one person as a hygienic procedural condition. Use in children younger than 6 years of age requires specific professional guidance.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Iliadin Lub


Evidence for Symptomatic Relief in Acute Rhinitis

Research examined the combination of Oxymetazoline and Dexpanthenol in studies relevant in trials assessing short-term or episodic symptom patterns, particularly focusing on outcomes related to physical discomfort such as nasal congestion. Study designs included randomized controlled trials (RCTs) and active-controlled comparative studies, which represent randomized study designs. Researchers monitored subjective nasal symptom scores and objective nasal patency (airway resistance).

Research explored whether the combination, when compared to decongestant monotherapy, was associated with different outcomes. Some findings have indicated that the combination group was associated with certain differences in mean nasal symptom scores and different durations reported for symptom resolution. Research on the decongestant component alone describes that its action was observed in trials with measured timing, and its effects were studied for periods up to 12 hours. Follow-up durations were limited to short-term studies, primarily covering the acute period of the illness (often 5 to 8 days).


Research on Mucosal Support and Local Tolerability

Research has explored the product's use in settings relevant to outcomes linked to inflammatory or irritative states of the nasal mucosa. Controlled clinical trials were used in research examining patient-reported outcomes describing local irritation and overall comfort. Researchers also tracked the incidence of rebound congestion as an outcome related to systemic or functional imbalance.

In a clinical trial, when the combination was observed in comparison to decongestant monotherapy, findings describe patterns where the combination group exhibited different reported incidences of rebound congestion. The same research also reported that patients described different outcomes related to local nasal irritation when using the combination compared to the comparator. The inclusion of Dexpanthenol in the product is based on scientific data showing patterns related to cell proliferation, which is relevant in evidence describing how symptoms are measured during conditions linked to inflammatory states.


What Is Still Uncertain About the Research Base

Limited information for long-term outcomes exists regarding the use of the fixed combination beyond the intermediate follow-up periods found in supportive care studies. Data for special populations, including children and older adults with comorbidities, remain insufficient. While comparative studies exist, the evidence base includes heterogeneity, such as studies where Dexpanthenol was observed in combination with Xylometazoline, which necessitates class extrapolation when drawing conclusions about the Oxymetazoline combination.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Iliadin Lub (FAQ)


Q: How quickly can I expect Iliadin Lub to start working?

A: Studies on the decongestant component indicate that the onset of action is rapid. Measured timings in product information describe effects that have been observed to begin within one minute after application to the nasal lining.


Q: How long does the effect of Iliadin Lub usually last?

A: Official administration instructions for this product state that application should occur no more often than every 10 to 12 hours. This frequency pattern aligns with regulatory information describing the duration of effect for the active decongestant component as lasting up to 12 hours.


Q: Can Iliadin Lub be used by children?

A: Regulatory documents establish the use of this product for children 6 years of age and older. For children who are under 6 years of age, official labeling indicates that professional guidance is recommended.


Q: What is the typical age range for adult use of Iliadin Lub?

A: Official guidelines generally reference use for adults and children 6 years of age and older. The established formulas are typically defined for this group, distinguishing them from specific formulations intended for infants or very young children.


Q: Is it okay to use Iliadin Lub with common pain relievers?

A: Official regulatory reviews confirm that, due to the topical administration, the product has a low potential for clinically significant systemic interactions. This low potential suggests that it is generally not expected to alter the clearance of most oral pain relievers.


Q: Can people with a history of heart issues use Iliadin Lub?

A: Regulatory documents state that the medicine is contraindicated for use in patients with severe cardiovascular diseases, such as severe hypertension. For individuals with other heart disease or hypertension, official labels state the product should be used only after consultation with a medical practitioner.


Q: Can Iliadin Lub be used for allergies?

A: Yes, official regulatory labeling describes this product as providing temporary relief of nasal congestion that may be associated with hay fever and upper respiratory allergies, in addition to congestion from the common cold.


Q: Is Iliadin Lub the same as other products with the name Iliadin?

A: Iliadin Lub is defined as a fixed-dose combination product containing two active ingredients: the decongestant Oxymetazoline and the epithelial protectant Dexpanthenol. Other products in the Iliadin range may contain different active ingredients or concentrations, such as single-ingredient Oxymetazoline solutions.


Q: Is there a maximum number of days Iliadin Lub should be used continuously?

A: Yes, official regulatory guidance explicitly instructs that treatment with this product should not exceed 3 consecutive days. Continuous or prolonged application falls outside of the established use protocol due to the risk of conditions like rebound congestion.


Q: Are there any studies or research on the effectiveness of Iliadin Lub?

A: Yes, regulatory summaries indicate that research has examined the combination of Oxymetazoline and Dexpanthenol in studies. These include randomized controlled trials relevant to outcomes for nasal congestion relief and mucosal support.


Q: Does using Iliadin Lub have any effect on my blood pressure?

A: Hypertension (high blood pressure) is listed in official documents as an adverse reaction, particularly associated with prolonged administration or overdose. Cautions are also documented for use in patients with pre-existing hypertension due to potential additive effects on the vascular system.


Q: What kind of nasal dryness is Iliadin Lub intended to help with?

A: The product includes the active ingredient Dexpanthenol, which is designed to support the cellular metabolic processes needed for the repair of the nasal epithelial barrier. This action is relevant to maintaining mucosal integrity and addressing irritation or dryness.


Q: Why is there a specific instruction about the angle of the head when using Iliadin Lub?

A: Administration instructions for the spray form may specifically state "Do not tilt head backward while spraying." This procedural constraint helps ensure the medicine reaches the nasal lining as intended for topical relief, avoiding runoff into the throat.


Q: What are the main differences between Iliadin Lub and Iliadin Plain?

A: Iliadin Lub is a combination product that includes the decongestant Oxymetazoline and the epithelial protectant Dexpanthenol. Plain, single-ingredient products typically only contain the decongestant component.


Q: Is Iliadin Lub known to cause drowsiness?

A: Drowsiness itself is not explicitly listed as a common effect. However, official documents do mention less frequent effects on the central nervous system, such as insomnia, nervousness, and irritability.


Q: Has Iliadin Lub been reviewed or approved by major health organizations?

A: Yes, the regulatory information for the drug is published and maintained by government agencies such as the FDA and regulatory bodies in other countries. This indicates the product has undergone formal review and has an established regulatory status for its intended use.


Q: Can I use Iliadin Lub if I have a cold, or only for dry nose?

A: Official labeling states the product provides temporary relief of nasal congestion due to the common cold. Its composition also includes an agent that supports mucosal integrity, which is relevant to symptoms of dry or irritated nasal linings.


Q: What evidence exists about the use of Iliadin Lub in patients with specific chronic conditions?

A: Official summaries of the research base indicate that data for special populations remain insufficient. This includes older adults with comorbidities (multiple pre-existing conditions) and others with specific long-term health issues.


Q: How is the safety profile of Iliadin Lub generally described in official sources?

A: The safety profile distinguishes common, local adverse effects (like nasal discomfort) from the potential for serious systemic risks. These serious risks, primarily involving cardiovascular and central nervous system events, are generally associated with high or prolonged exposure.


Q: Is it necessary to tilt the head back completely when using the drops?

A: Administration instructions for the spray form specifically advise against tilting the head backward while spraying. This ensures proper application to the nasal mucosa for the intended topical effect.


Q: Can Iliadin Lub be used with other nasal sprays?

A: Official labeling may include specific timing rules, such as requiring a 24-hour separation, before using certain other nasal products. Caution is advised, as the decongestant effect could be additive with other products that contain sympathomimetic agents.


Q: What is the role of the 'Lub' part of the product?

A: The 'Lub' part references the inclusion of Dexpanthenol, which is integrated to promote mucosal integrity restoration. This ingredient supports the cellular processes required for the natural repair of the nasal epithelial barrier.


Q: Are there any known food interactions with Iliadin Lub?

A: Official labeling for the active decongestant component may advise limiting intake of caffeine from food and beverages. This is because excessive caffeine could potentially worsen sympathomimetic side effects like nervousness or palpitations.


Q: Does Iliadin Lub have a specific storage temperature requirement?

A: Yes, official documents specify that the product must be stored at a temperature below 25^\circC. It is also required to be protected from freezing and excessive heat.


Q: What is the generally described mechanism for the active ingredient?

A: The primary mechanism of action involves the decongestant component activating specific receptors on blood vessels in the nasal lining. This action causes the vessels to narrow (vasoconstriction), which reduces swelling and helps relieve congestion.


Q: Is Iliadin Lub intended only for nasal use?

A: Yes, official administration guidelines strictly designate the medicine for Topical Intranasal administration. It is formulated as an aqueous solution to be applied directly to the nasal mucosa.

Advertisements

How should Iliadin Lub be stored and disposed of?

How to Store and Dispose of Iliadin Lub

Official regulatory documents define specific environmental constraints and disposal rules for this nasal solution.

Storage Requirements

Iliadin Lub must be stored at a temperature below 25 C. The product is required to be protected from freezing and excessive heat. For safety, the medicine must be consistently stored out of the sight and reach of children.

Stability and Container

To ensure product stability, the container should be kept well closed. Furthermore, after the first opening of the container, the product must be used within 3 months.

Disposal Instructions

Unused or expired medicine must not be thrown away via wastewater or household waste. Disposal should follow established local requirements, often involving returning the product to a pharmacy or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Iliadin Lub found in:

A-Z Index: